JP6706204B2 - 新規２，４−ジニトロフェノール製剤およびその使用法 - Google Patents

新規２，４−ジニトロフェノール製剤およびその使用法 Download PDF

Info

Publication number
JP6706204B2
JP6706204B2 JP2016537894A JP2016537894A JP6706204B2 JP 6706204 B2 JP6706204 B2 JP 6706204B2 JP 2016537894 A JP2016537894 A JP 2016537894A JP 2016537894 A JP2016537894 A JP 2016537894A JP 6706204 B2 JP6706204 B2 JP 6706204B2
Authority
JP
Japan
Prior art keywords
subject
dnp
compound
liver
erdnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016537894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530279A5 (enExample
JP2016530279A (ja
Inventor
ジェラルド アイ． シュールマン
ジェラルド アイ． シュールマン
レイチェル ジャミソン ペリー
レイチェル ジャミソン ペリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52587363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6706204(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yale University filed Critical Yale University
Publication of JP2016530279A publication Critical patent/JP2016530279A/ja
Publication of JP2016530279A5 publication Critical patent/JP2016530279A5/ja
Priority to JP2019162622A priority Critical patent/JP6913137B2/ja
Application granted granted Critical
Publication of JP6706204B2 publication Critical patent/JP6706204B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016537894A 2013-08-30 2014-08-29 新規２，４−ジニトロフェノール製剤およびその使用法 Active JP6706204B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019162622A JP6913137B2 (ja) 2013-08-30 2019-09-06 新規２，４−ジニトロフェノール製剤およびその使用法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361872294P 2013-08-30 2013-08-30
US61/872,294 2013-08-30
US201361919003P 2013-12-20 2013-12-20
US61/919,003 2013-12-20
PCT/US2014/053406 WO2015031756A1 (en) 2013-08-30 2014-08-29 Novel 2,4-dinitrophenol formulations and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019162622A Division JP6913137B2 (ja) 2013-08-30 2019-09-06 新規２，４−ジニトロフェノール製剤およびその使用法

Publications (3)

Publication Number Publication Date
JP2016530279A JP2016530279A (ja) 2016-09-29
JP2016530279A5 JP2016530279A5 (enExample) 2017-09-07
JP6706204B2 true JP6706204B2 (ja) 2020-06-03

Family

ID=52587363

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016537894A Active JP6706204B2 (ja) 2013-08-30 2014-08-29 新規２，４−ジニトロフェノール製剤およびその使用法
JP2019162622A Active JP6913137B2 (ja) 2013-08-30 2019-09-06 新規２，４−ジニトロフェノール製剤およびその使用法
JP2021113956A Active JP7359809B2 (ja) 2013-08-30 2021-07-09 新規２，４－ジニトロフェノール製剤およびその使用法
JP2023127746A Pending JP2023133603A (ja) 2013-08-30 2023-08-04 新規２，４－ジニトロフェノール製剤およびその使用法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019162622A Active JP6913137B2 (ja) 2013-08-30 2019-09-06 新規２，４−ジニトロフェノール製剤およびその使用法
JP2021113956A Active JP7359809B2 (ja) 2013-08-30 2021-07-09 新規２，４－ジニトロフェノール製剤およびその使用法
JP2023127746A Pending JP2023133603A (ja) 2013-08-30 2023-08-04 新規２，４－ジニトロフェノール製剤およびその使用法

Country Status (5)

Country Link
US (4) US10786466B2 (enExample)
EP (1) EP3038611B1 (enExample)
JP (4) JP6706204B2 (enExample)
CN (2) CN110302385A (enExample)
WO (1) WO2015031756A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021165309A (ja) * 2013-08-30 2021-10-14 イエール ユニバーシティ 新規２，４−ジニトロフェノール製剤およびその使用法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116617195A (zh) 2015-01-22 2023-08-22 米托充制药公司 脑源性神经营养因子的诱导表达
DE102015016801A1 (de) * 2015-12-23 2017-06-29 Christian Windisch Chemotherapeutisches Verfahren zur Behandlung maliger Geschwülste durch "Entkopplung" der oxidativen Phosphorilierung ("Krebsatmung") in aerob glycolysierenden Zellen (Krebszellen)
JP7021098B2 (ja) * 2016-03-07 2022-02-16 マイトコン ファーマシューティカルズ， インコーポレイテッド 神経筋、神経変性、自己免疫、発達、外傷性脳損傷、震とう、ドライアイ疾患および／または代謝性疾患のｄｎｐおよびｄｎｐプロドラッグ処置
GEP20217227B (en) 2017-01-06 2021-02-25 Pharmaceuticals Inc Rivus Novel phenyl derivatives
WO2019217164A1 (en) * 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
US20200397807A1 (en) 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
CN110237033A (zh) * 2019-07-30 2019-09-17 成都医学院 一种2,4二硝基苯酚注射液及其制备方法和用途
CN110302154B (zh) * 2019-07-30 2021-09-10 成都医学院 一种2,4-二硝基苯酚脂肪乳及其制备方法和用途
CN113045428B (zh) * 2019-12-26 2022-04-22 中国农业大学 化合物及其在减脂中的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA774573A (en) 1967-12-26 Sehring Richard Derivatives of 2-hydroxy-3,5-dinitrobenzyl alcohol
US2183589A (en) 1939-12-19 Derivatives of compounds of the
US1695656A (en) 1927-03-10 1928-12-18 Firm Gehe & Co A G Method of producing narcotica
US3081224A (en) 1959-01-21 1963-03-12 American Cyanamid Co Methods of removing helminths employing halogenated nitrophenols and their derivatives
NL301998A (enExample) 1962-12-27 1900-01-01
DE3313905A1 (de) 1983-04-16 1984-10-25 Henkel KGaA, 4000 Düsseldorf Neue 2.4-diaminophenolether als kuppler fuer oxidationshaarfaerbemittel
DE3515339A1 (de) 1985-04-27 1986-10-30 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von 2,4-dinitrophenylethern
CN1011660B (zh) * 1986-04-23 1991-02-20 吴佩璇 一种含三硝基苯、田螺的药品合成方法
US5078908A (en) 1989-10-02 1992-01-07 Allergan, Inc. Methods for generating chlorine dioxide and compositions for disinfecting
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
IN192400B (enExample) * 1995-06-14 2004-04-10 Council Scient Ind Res
CA2180903A1 (en) 1995-07-11 1997-01-12 Kunio Sugisawa Pesticidal composition to noxious organisms
EP1073693A1 (en) 1998-04-24 2001-02-07 Eastman Chemical Company Coprecipitation of cellulose esters with functional additives and compositions thus obtainable
US7635722B1 (en) * 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
EP1429734B1 (en) * 2001-09-21 2007-12-26 Egalet A/S Controlled release solid dispersions of carvedilol
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
EP1575575B1 (en) 2002-11-08 2010-05-19 High Point Pharmaceuticals, LLC Safe chemical uncouplers for the treatment of obesity
WO2007050673A2 (en) 2005-10-25 2007-05-03 University Of Florida Cyclin dependent kinase inhibitors
EP2196453A1 (en) 2008-12-10 2010-06-16 Cellvir Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents
WO2011053825A2 (en) * 2009-10-30 2011-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment or prevention of mitochondrial diseases
JP2013209295A (ja) * 2010-10-13 2013-10-10 Takeda Chem Ind Ltd ペプチド誘導体
CN110302385A (zh) * 2013-08-30 2019-10-08 耶鲁大学 新型2，4-二硝基苯酚制剂和使用其的方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021165309A (ja) * 2013-08-30 2021-10-14 イエール ユニバーシティ 新規２，４−ジニトロフェノール製剤およびその使用法
JP7359809B2 (ja) 2013-08-30 2023-10-11 イエール ユニバーシティ 新規２，４－ジニトロフェノール製剤およびその使用法

Also Published As

Publication number Publication date
CN105682653A (zh) 2016-06-15
CN110302385A (zh) 2019-10-08
US20250228793A1 (en) 2025-07-17
US11883369B2 (en) 2024-01-30
JP2023133603A (ja) 2023-09-22
JP6913137B2 (ja) 2021-08-04
US20200352879A1 (en) 2020-11-12
EP3038611A1 (en) 2016-07-06
WO2015031756A1 (en) 2015-03-05
HK1225607A1 (en) 2017-09-15
JP2021165309A (ja) 2021-10-14
US10786466B2 (en) 2020-09-29
JP7359809B2 (ja) 2023-10-11
US20220339121A1 (en) 2022-10-27
JP2016530279A (ja) 2016-09-29
EP3038611B1 (en) 2024-04-17
US20160199310A1 (en) 2016-07-14
JP2020002166A (ja) 2020-01-09
US11433033B2 (en) 2022-09-06
CN105682653B (zh) 2022-10-21
EP3038611A4 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
JP7359809B2 (ja) 新規２，４－ジニトロフェノール製剤およびその使用法
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
EP2773354B1 (en) Oral immediate release formulations for substituted quinazolinones
Ho et al. Liposome-encapsulated curcumin attenuates HMGB1-mediated hepatic inflammation and fibrosis in a murine model of Wilson’s disease
US11517540B2 (en) Restoring physiology in iron-deficient organisms using small molecules
JP2009506043A (ja) Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
KR20190034550A (ko) 간성 뇌병증의 치료 방법
HK1225607B (en) Sustained-release pharmaceutical composition comprising 2,4-dinitrophenol
Cetin et al. Paradigm shift in obesity treatment: an extensive review of current pipeline agents
US20240100001A1 (en) Denatonium salt for use in preventing, preventing progression and treating fatty liver diseases
WO2025014754A1 (en) Compositions containing, and combination therapies using bempedoic acid and a glp-1 receptor agonist
Ouyang The Involvement of Receptor Interacting Protein Kinase 1 (RIPK1) in the Pathogenesis of Acute Pancreatitis
HK1201751B (en) Oral immediate release formulations for substituted quinazolinones

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190906

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200515

R150 Certificate of patent or registration of utility model

Ref document number: 6706204

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250